BostonGene, developer of AI models for tumor and immune biology, receives three Gold Stevie Awards at the 2026 Stevie® Awards for Technology Excellence. The company was recognized in three biotechnology categories. They are New Product of the Year, Technology Breakthrough of the Year, and Company of the Year.
The honors recognize BostonGene’s contributions to AI in drug development. Its technology uses biologically grounded simulations to study how tumors and immune systems might respond to treatments. This means that pharmaceutical companies can evaluate possible therapeutic effects before clinical trials are started.
Prior clinical data is often utilized with traditional AI methods for treatment effect prediction. But BostonGene is taking a different tack with its Simulational artificial intelligence (AI) technology. The platform models therapeutic intervention effects on tumor and immune biology. It also translates multimodal patient data into disease-level simulations and actionable biological insights.
This approach helps biopharmaceutical companies prioritize drug development programs. It also supports patient selection and more precise clinical trial planning.
BostonGene Highlights the Role of Simulational AI in Drug Development
“Most AI in drug development learns from what has already happened,” said Andrew Feinberg, President and CEO of BostonGene. “We built our AI models to simulate what will happen, grounded in how a patient’s tumor and immune system actually behave. That lets our partners see a therapy’s likely effect before the first patient is enrolled. These awards recognize that shift. Our focus is helping partners reduce development risk, make confident pipeline decisions, and bring the right therapies to the patients who need them.”
BostonGene Earns Recognition Across Three Biotechnology Categories
BostonGene received Gold Stevie Awards in the following categories:
Company of the Year – Biotechnology
The award recognizes BostonGene’s integrated approach to biotechnology and drug development. The company combines biologically grounded AI, proprietary multimodal patient data, and clinical-grade laboratory capabilities.
Moreover, its collaborations with global biopharmaceutical companies have supported drug development decisions. These collaborations helped prioritize indications with strong biological evidence. They also identified a biomarker-selected patient population with nearly three times the response rate.
New Product of the Year – Biotechnology
BostonGene’s Foundation Model for Drug Effect Prediction received recognition in this category. The model advances drug development through prospective, biology-driven therapeutic evaluation.
It utilizes a proprietary diffusion-based architecture to produce patient-specific digital representations. These representations encode tumor and immune biology . Furthermore, the model shows how treatments may act on molecular, cellular and tissue levels.
The technology links a drug’s mechanism of action to potential efficacy and immune-mediated safety risks, offering useful information prior to clinical testing. This allows development teams to make better choices earlier in the drug development process.
Technology Breakthrough of the Year – Biotechnology
BostonGene also received recognition for its Multimodal AI for Trial Design Optimization. The technology supports pharmaceutical companies in improving clinical trial design.
It integrates tumor, immune and clinical data to guide patient selection. In addition, it supports biomarker strategies and adaptive trial planning during development.
It converts complex and incomplete data sets into actionable development insights. This way, biopharmaceutical partners can manage development risks and prioritize patients who may benefit most from treatment.
BostonGene’s platform is supported by a CLIA-certified and CAP-accredited laboratory. The company also has broad clinical validation of its technology.
It is also backed by peer-reviewed research on its underlying methodologies and clinical reliability. Its research has been published in top scientific journals. They include Cancer Cell, Cancer Discovery, Nature, Cell Reports Medicine, Frontiers in Oncology, and Modern Pathology.
In addition to presenting our research at high impact scientific meetings such as AACR, ASCO, ASH, ESMO, SITC, SABCS and JSMO.
BostonGene continues to drive progress in the areas of precision oncology, drug development and clinical trial optimisation utilizing our AI-powered biotech platform.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
